About this medicine

Buspirone is a non-benzodiazepine medicine for anxiety. A UK product licence, a treatment guideline and a local formulary answer different questions: authorisation does not guarantee NHS selection or pharmacy stock. This article distinguishes the checked manufacturers because their maximum-dose instructions differ.

What is this medicine used for?

The checked UK products cover short-term anxiety disorders or anxiety symptoms, including anxiety accompanying depressive symptoms. Buspirone is not licensed as stand-alone treatment for depression in these records. This is not an unrestricted licence for every condition associated with anxiety.

Which warning signs need help?

Urgent assessment is needed for severe allergy or agitation with fever, sweating and muscle twitching, which can indicate serotonin toxicity. Seek immediate medical advice after an overdose, even if symptoms initially seem mild. Use emergency services in the country where you actually are.

How do I take it safely?

Viatris reference dosing starts at 5 mg two or three times daily. After several weeks, increases may be made in 5 mg steps at 2–3-day intervals; usual totals are 15–30 mg/day, maximum 60 mg. Strides 7.5 mg tablets instead specify 45 mg/day maximum. These are product references, not a personal schedule.

What side effects should I know about?

Headache, dizziness, nausea, nervousness and sleepiness can occur. Gastrointestinal discomfort, sweating or sleep disturbance may also need review. Avoid driving or hazardous tasks when affected; report troublesome effects rather than adjusting the dose independently.

Who needs extra care with this medicine?

The checked products prohibit use in epilepsy, severe liver or kidney impairment and acute intoxication with certain sedating medicines or alcohol. Glaucoma, myasthenia gravis and less severe kidney or liver disease need specific assessment. These are product precautions, not an invitation to self-screen for suitability.

Can it affect my other medicines?

Do not combine with MAO inhibitors without prescriber review; the UK products advise against concomitant use. Other serotonergic medicines, including some antidepressants and tramadol, can increase serotonin-toxicity risk. CYP3A4 inhibitors such as azole antifungals and some antibiotics increase exposure; rifampicin and some epilepsy medicines reduce it. Verapamil and diltiazem also interact. Avoid large amounts of grapefruit juice.

What check-ups will I need?

Follow-up should assess anxiety, delayed response, dizziness and interactions, with particular attention to kidney or liver problems. A lack of immediate relief is not a reason to take extra tablets. Reassess continuing need because the UK indication is short-term.

What about pregnancy, breastfeeding and age?

Trials have not established useful treatment benefit for under-18s in the checked anxiety indication. Pregnancy is generally avoided as a precaution; breastfeeding requires an individual risk–benefit discussion because human milk data are limited. Do not interpret limited evidence as proof of safety or inevitable harm.

What if I miss a dose or want to stop?

Take tablets consistently with or without food and swallow with water. If a dose is forgotten, take it when remembered unless the next is nearly due; never double up. Discuss stopping with the prescriber. A separate, gradual benzodiazepine withdrawal plan may still be needed.

How does it work?

Buspirone changes signalling involving serotonin, a chemical messenger used by nerve cells. It acts at serotonin receptors, proteins that detect messages and affect a cell’s activity. Its complete anxiety-relieving mechanism is not fully understood, and benefit can take several weeks to develop.

Buspirone does not act at the same binding site as benzodiazepines, a different group of medicines that can have rapid calming effects. It is therefore not an interchangeable option for immediate relief. It also does not prevent benzodiazepine withdrawal, the symptoms that can follow reducing or stopping those medicines, or replace a supervised taper, meaning a gradual reduction.

How does it affect my body?

Compared with benzodiazepines, buspirone has little muscle-relaxant or anticonvulsant activity. Dizziness and drowsiness can nevertheless affect daily activities. It does not protect someone from withdrawal when a benzodiazepine is stopped.

How does my body process it?

Oral absorption is rapid, followed by substantial first-pass metabolism. CYP3A4 is important; the active metabolite 1-PP has uncertain clinical significance. The checked Viatris text gives a 2–11-hour half-life range. Food changes exposure, so consistency matters.

How do treatment options differ?

NICE's generalised-anxiety pathway discusses psychological treatment and antidepressant options; medicine licensing alone does not establish first-line status. Benzodiazepines are reserved for brief crisis use in that guidance. NICE recommendations do not establish identical service access throughout all four UK nations.

A closer look at the science

It is an azapirone with activity at serotonin 5-HT1A receptors: the product description distinguishes presynaptic agonism from postsynaptic partial agonism. Dopamine D2 effects are described, but their contribution to anxiety relief remains uncertain.

How was this medicine developed?

The checked Viatris 5 mg authorisation records February 2001. This is that product's regulatory history, not the discovery date of buspirone. Its current text and the Strides text retain different dose ceilings, illustrating why manufacturer-level checking matters.

Sources and References

  1. Buspirone Hydrochloride 5 mg tablets: SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  2. Buspirone Hydrochloride 10 mg tablets: SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  3. Buspirone Hydrochloride 7.5 mg tablets: SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  4. Buspirone Hydrochloride 5 mg and 10 mg tablets: patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  5. NICE CG113: Generalised anxiety disorder and panic disorder in adults

    Scope: United Kingdom.

  6. Buspirone hydrochloride 7.5 mg tablets: patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  7. Buspirone hydrochloride tablets prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Description; Clinical Pharmacology; Precautions—Potential for Withdrawal Reactions in Sedative/Hypnotic/Anxiolytic Drug-Dependent Patients. This does not establish UK product authorisation or prescribing..

  8. What Is a Neurotransmitter? — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: How Neurotransmitters Work; Types of Neurotransmitters. This does not establish UK product authorisation or prescribing..

  9. Serotonin syndrome: MedlinePlus Medical Encyclopedia
  10. Monitoring a person during and after antidepressant switching – NHS SPS - Specialist Pharmacy Service – The first stop for professional medicines advice

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top